Janus kinase inhibitors

Where the papers sit

14 papers from the last 6 months study janus kinase inhibitors directly · updated from PubMed 3 Oct 2026

• Real-World JAK Inhibitor Use

  Clinical use is being assessed across inflammatory disease, systemic sclerosis, myelofibrosis and post-infectious hyperinflammation. Longitudinal response, flare patterns, treatment duration and infection remain recurring outcomes. Combination therapy, including biologic-JAK inhibitor regimens, is being explored for refractory systemic autoinflammatory disease. Evidence remains disease-specific rather than convergent, leaving comparative effectiveness and long-term safety open.

  5 papers · 35.7%

• Rheumatoid Arthritis JAK Outcomes

  Rheumatoid arthritis care is shifting toward treatment-aware selection of JAK inhibitors against biologics such as sarilumab. Observational studies repeatedly examine effectiveness, discontinuation, glucocorticoid use and acute coronary events across tofacitinib, filgotinib and upadacitinib. Risk appears dependent on age, baseline characteristics and treatment context rather than drug exposure alone. Better cardiovascular stratification and durable comparative data remain open needs.

  5 papers · 35.7%

• Alopecia Areata Treatment Choices

  Treatment selection in alopecia areata is moving toward comparisons of ritlecitinib, baricitinib and tofacitinib across disease severity and age groups. Response differs between acute and nonacute disease, while paediatric studies add real-world safety data. Patients and clinicians weigh efficacy, speed of response, safety and treatment attributes differently. These findings support individualized JAK inhibitor choice, but comparative long-term outcomes remain limited.

  4 papers · 28.6%